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Purpose: Although axillobifemoral bypass procedures have a lower mortality rate than aorto- 
bifemoral bypass procedures, they are limited by decreased patency, moderate hemodynamic 
improvement, and the need for general anesthesia. This report describes an alternative 
approach to bilateral aortoiliac occlusive disease using unilateral endovascular aortofemoral 
bypass procedures in combination with standard femorofemoral reconstructions. 
Methods: Seven patients who had bilateral critical ischemia nd tissue necrosis in associa- 
tion with severe comorbid medical illnesses underwent implantation of unilateral aor- 
tofemoral endovascular grafts, which were inserted into predilated, recanalized iliac 
arteries. The proximal end of the endovascular graft was fixed to the distal aorta or 
common iliac artery with a Palmaz stent. The distal end of the graft was suture- 
anastomosed to the ipsilateral patent outflow vessel, and a femorofemoral bypass proce- 
dure was then performed. 
Results: All endovascular g afts were successfully inserted through five occluded and two 
diffusely stenotic iliac arteries tinder either local (1), epidural (5), or general anesthesia 
(1). The mean thigh pulse volume recording amplitudes increased from 9 - 3 mm to 30 - 
7 mm and from 6 -+ 2 mm to 26 - 4 mm ipsilateral and contralateral.to the aortofemoral 
graft insertion, respectively. In all cases the symptoms completely resolved. Procedural 
complications were limited to one local wound hematoma. No graft thromboses occurred 
during follow-up to 28 months (mean, 17 months). 
Conclusions: Endovascular iliac grafts in combination with standard femorofemoral 
bypass grafts may be an effective alternative to axillobifemoral bypass in high-risk patients 
who have diffuse aortoiliac occlusive disease, particularly when bilateral axillary-subcla- 
vian disease is present. (J Vasc Surg 1996;24:984-97.) 
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Axillobifemoral bypass (Ax-bFB) has become a 
treatment option for managing bilateral ower ex- 
tremity critical ischemia caused by aortoiliac disease 
in high-risk patients who would not be expected to 
tolerate the more durable aortobifemoral bypass 
(ABFB). Although Ax-bFB is associated with a lower 
mortality rate than ABFB in high-risk patients, its
effectiveness may be significantly impaired by several 
factors1,2: the need for general anesthesia, dissection 
of  an unaffected vascular bed with potential upper 
extremity embolization, a high rate of  graft infection, 
and compromised patency rates that require addi- 
tional operations? ,3-s Moreover, the potential for 
poor hemodynamic and functional improvement asa 
result of  insufficient donor artery flow and the long 
grafts required may further hamper procedural suc- 
cess, 8-12 
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Fig, 1. EVG and delivery systems. A, Endovascular thin-walled PTFE graft. A Palmaz balloon- 
expandable stent (S) is sutured to graft with four diametrically opposed "U" sutures (two on 
each side), which permit one half of the stent o protrude from graft. B, Double balloon catheter 
introducer/delivery system used for delivery and deployment ofendovascular stented grafts. In 
this system, the introducer catheter isequipped with two separate balloon catheters. Balloon A 
functions as a mechanism to form a tapered tip to catheter system and also allows pressurization 
of the flexible sheath (C) after saline is injected from port D. Second balloon B functions to 
deploy overlying Palmaz stent (S). With expansion of balloon B, EVG (G) becomes firmly fixed 
to underlying arterial wall. V, hemostafic valve mechanism. C, Alternative delivery system 
consisting of single balloon catheter with two balloons on a single shaft. First balloon serves as 
a tip balloon (A), and stent-graft complex ismounted on to independent deploying balloon (B). 
Endovascular techniques that are catheter- and 
guidewire-based are another less-invasive treatment 
option. Percutaneous balloon angioplasty with or 
without he use of  vascular stents has been extensively 
used for managing aortoiliac occlusive disease. Thus 
far, however, these catheter-based techniques have 
proven utility only for. short-segment lesions in pa- 
tients who have minimal symptoms, and they have 
not been proved effective for treating patients who 
have multilevel critical ischemia. 13-16 The introduc- 
tion of  endovascular g afts (EVGs) appears to have 
extended the potential uses of  angioplasty and stent- 
ing to include the treatment of critical ischemia s a 
result of aortoiliac occlusive disease. 17-2] Although 
favorable short-term and middle-term results have 
been shown in unilateral iliac disease, bilateral iliac 
occlusions were typically more technically challeng- 
ing and suggested further procedure modifications 22 
Porter et al. 2a were the first to recognize the 
potential of using endovascular techniques for the 
treatment of  bilateral aortoiliac disease. Their initial 
report suggested a role for balloor, angioplasty in the 
treatment of a stenotic lesion in the donor iliac arteit¢ 
with the subsequent performance ofa femorofemoral 
bypass procedure (FFB). Although these authors em- 
phasized the efficacy of  balloon angloplasty in their 
seminal paper, this technique did not have broad 
application because success was limited to treating 
focal common iliac artery disease. 
We have combined EVGs and FFBs for the treat- 
ment of  bilateral ong-segment aortoiliac occlusive 
disease that causes limb-threatening ischemia in those 
patients who have multiple medical illnesses or have 
previously undergone abdominal aortic surgery. This 
method not only simplifies the complex endovascular 
procedure that is required in bilateral reconstruction, 
but may also achieve better hemodynamic, anglo- 
graphic, and clinical results. 
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METHODS 
Patients. Between March 1994 and December 
1995, seven patients who had fimb-threatening isch- 
ernia and tissue necrosis as a result of aortoiliac and 
femoropopliteal occlusive disease were treated at the 
Montefiore Medical Center with a unilateral endo- 
vascular aortofemoral or iliofemoral EVG in combi- 
nation with a standard FFB reconstruction. Four 
were men and three were women; their ages ranged 
from 59 to 77 years (mean, 69 years). All patients had 
grade 5 ischemia (SVS/ISCVS criteria24), and had No. 2 
multiple, coexisting medical problems, including a M/70 
history of a previous myocardial infarction in all cases, No. 3 
recent myocardial infarction, congestive heart failure, F/70 
and chronic obstructive pulmonary disease (Table I). 
Four patients (57%) had a history of one or more 
No. 4 
abdominal vascular operations. Pulse volume record- F/77 
ings (PVRs), ankle-brachial indexes, and angiograms No. 5 
with femoropopliteal nd tibial runoff views were M/71 
performed in all patients before and after each inter- No. 6 
vention. The patency of the superficial femoral artery F/59 
and the distal runoff score were determined from the No. 7 
preoperative angiograms according to the SVS/ M/71 
ISCVS criteria. Each patient's risk and severity scores 
for operative treatment were calculated in accordance 
with Rutherford's criteria and the SVS/ISCVS stan- 
dards (Table 1). 24,25 
EVG devices. The EVGs used in this study were 
composed of Palmaz balloon-expandable st nts (30 
ram, Johnson and Johnson Interventional Systems, 
Warren, N.J.) and 6-mm thin-walled polytetrafluoro- 
ethylene (PTFE) grafts (Wi .  Gore and Associates, 
Flagstaff, Ariz.; and IMPRA, Inc., Tempe, Ariz.). 
Each stent was attached to the proximal end of the 
PTFE graft by four CV-6 PTFE sutures o that one 
half of the stent protruded from the end of the graft 
(Fig. 1, A). After suturing the graft to the stent, the 
stent-graft complex was mounted on to an angio- 
plasty balloon by manually crimping the stent over 
the balloon surface. The delivery system consisted of 
an 8 mm × 3 cm angioplasty balloon (Blue Max or 
PEMT, Medi-tech Corp., Watertown, Mass.) and a 
second balloon catheter (tip balloon). The entire stent, 
graft, and balloon complex was then wrapped around 
the shaft of the tip balloon and inserted into a 14F 
delivery sheath (Fig. 1, B). The 6 man × 4 cm tip 
balloon was adjusted so that one-third of the tapered 
portion of the balloon protruded from the distal portion 
of the delivery sheath. A modified form of this delivery 
system consisted of a dual balloon catheter (tip balloon 
and stent deploying balloon) on a single shaft (Fig. 1, 
C). In both delivery system configurations, inflation of 
the tip balloon sealed the distal end of the sheath, 
Table I. Clinical Characteristics 
Patient characteristics 
Patient Patient 
no. risk 
Sex/age Comorbid disease Previous surgery score* 
No. I Previous MI 7 previous failed 0.4 
M/63 vascular 
reconstructions, 
including an 
ABF 
Recent MI, atrial 
fibrillation, mild 
COPD 
Previous MI 
Previous MI, CHF, 
angina 
Previous MI, CAD, 
CHF, Stroke, 
moderate COPD 
Previous MI, CAD, 
CRF 
Previous MI, on 
pacemaker, 
moderate COPD 
Aborted ABF due 
to bleeding and 
severe aortic 
calcification 
Failed Ax-bFB 
Failed Ax-bFB 
(2 times); 
sympathectomy 
Gastrectomy, 
failed ABFB 
(2 times), failed 
Ax-bFB 
1.1 
1.4 
1.6 
1.4 
1.6 
*In accordance with Rutherford's criteria. 2s 
f in accordance with the SVS/ISCVS reporting standards. 24 
DM, diabetes mellitus; M/, myocardial infarction; COPD, chronic 
obstructive pulmonary disease; CHF, congestive heart failure; 
CAD, coronary artery disease; CR~ chronic renal failure; OCC, 
occlusion; STE, stenosis. 
allowing sheath pressurization for variable flexibility and 
pushability and providing a tapered, smooth transition 
to the end of the defivery sheath. 
Determination of  side for EVG insertion and 
location of  stent deployment. The ifiac artery in 
which the EVG is deployed and the positioning of the 
proximal stent are determined by preoperative angio- 
graphic findings. The deployment of the EVG will 
likely result in the occlusion of all of the small 
branches along the vessel that is covered by the graft. 
The presence and quality of the internal i iac artery will, 
therefore, influence the side of EVG access and the site 
of deployment. Similarly, the length and degree of the 
common or external iliac artery disease will often deter- 
mine the technical difficulty associated with vessel recau- 
alization. Generally, it is easier and safer to racanalize 
through a stenotic lesion than through an occluded 
lesion. In addition, shorter lesions are easier to recana- 
lize. Using the algorithm outlined in Fig. 2, the classi- 
fication of disease patterns (type I, internal i iac artery is 
occluded or severely diseased bilaterally; type II, a good- 
quality internal i iac artery is present on one side; type 
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Severity scoring for operative weatment 
Right limb Left limb 
Clinical Runoff Lesion 
categort~ score'/" length 
Lesion Clinical Runoff Les ion Lesion Type of 
type category'/" score'/" length type procedure * DM Tobacco * 
5 7 20 cm OCC 5 7 32 cm OCC 3 - -  3 
4 5 16 cm STE 5 7 16 cm OCC 0 N IDDM 3 
4 3 19 cm OCC 5 3 19 cm OCC 2 N IDDM 1 
5 7 21 cm OCC 5 
4 8 13 cm STE 5 
5 21 cm OCC 2 N IDDM 0 
8 30 cm OCC 2 N IDDM 2 
4 1 6 cm OCC 5 
5 9 16 cm OCC 4 
3 8 cm OCC 0 - -  2 
1 13 cm STE 3 IDDM 1 
III, a goo&quality internal lilac artery is present bilater- 
ally), the side to be used for EVG insertion, and the 
location of the proximal stent were determined. 
Operative technique. Open dissection and ex- 
posure of the femoral arterial access site were per- 
formed. After systemic heparinization, alliliac arteries 
were successfully recanalized with a 0.035-inch y- 
drophilic guidewire (Glidewire, Medi-tech, Inc.) and 
an angled directional catheter under fluoroscopic 
guidance (BV 212, Philips, The Netherlands; or 
OEC Diasonics model 9000, OEC Medical Systems, 
Inc., Salt Lake City, Utah) (Fig. 3). After successful 
wire passage, an 8-mm-diameter angioplasty balloon 
was passed over the wire, and the iliac artery was 
dilated to a diameter of 8 mm along the entire length 
of the vessel (Fig. 4). The previously prepared EVG 
device was then inserted into the newly created tract 
within the arterial wall over the same guidewire (Fig. 
5). Once the fixation stem could be seen fluoroscop- 
ically to be located at the appropriate predetermined 
site, the tip balloon was deflated, and the sheath was 
then partially retracted to allow proximal stent expo- 
sure and deployment (Fig. 6). The delivery sheath 
was then completely withdrawn, permitting the re- 
dundant portion of the distal end of the EVG to 
emerge from the arteriotomy in the access vessel. The 
distal, redundant portion of the graft was then cut to 
an appropriate l ngth and was endoluminally hand- 
sewn into the patent, distal runoffvessel (Fig. 7). 
A 6-ram externally supported thin-walled PTFE 
graft (W.L. Gore and Associates) was used for the 
FFB in each patient. The arteriotomy site used for the 
insertion of the EVG served as the proximal anasto- 
motic site of the FFB. The graft was subcutaneously 
tunneled to the contralateral side and the recipient 
anastomosis was performed in a standard fashion to 
the patent, distal nmoffvessel (Fig. 8). 
Combined-segment occlusive disease was simul- 
taneously treated with either a femoropopliteal by- 
pass or a patch proftmdaplasty procedure. Those pa- 
tients who had tissue necrosis or a nonhealing ulcer 
tmderwent either simultaneous minor amputation or 
debridemenr. An intraoperative completion anglo- 
gram was performed in all patients. 
Follow-up studies. A follow-up arteriographic 
scan was performed inamediately afte r surgery in six of 
the seven patients within the first week. All patients 
underwent postoperative PVRs and a determination 
of the ankle~brachial index. The PVR amplitudes that 
were obtained before and after surgery were com- 
pared for each patient to determine the hemody- 
namic improvement that occurred. Additional PVRs, 
ankle-brachial indexes, and color duplex ultrasono- 
graphic evaluations were performed at regular inter- 
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YES 
Internal iliac artery~' 
is diseased and  | 
small bilaterally { 
NO I NO 
Internal iliac artery of~ 
equa good quality 
YES 
CLASSIFICATION COMPLETION 
1WPE II 
SIDE OF EVG LOCATION OF 
INSERTION PROXIMAL STENT 
Side with the shortest 
iliac occlusion or stenosis Aorta 
Side contralateral to Proximal Common 
patent or best internal Iliac Artery 
iliac artery 
• A 
~ iliac occlusion or stenosis 
TYPE III 
Side with the shortest . Proximal Common 
lilac Artery 
Fig. 2. Algorithm and classification of endovascular g afting for bilateral aortoiliac occlusive 
disease. Classification of distribution of disease, determination of appropriate side for graft 
insertion, and identification oflocation for proximal stent deployment may be approached using 
this algorithmic outline. 
vals (3 months, 6 months, and every 6 months there- 
after). A long-term course of  anticoagulafion 
medication was not used. 
RESULTS 
As shown in Table I, the mean patient risk score 
was 1.4 + 0.5 (mean + SD), and the mean runoff 
scores were 5.7 + 3 and 4.9 + 3 for right and left 
limbs, respectively. 
Coexisting comorbid illnesses precluded the use 
of general anesthesia n six of  the seven patients, and 
either epidural (5) or local anesthesia (1) was used. 
Technical success of recanalization and device inser- 
tion was achieved in each case in which it was at- 
tempted. The mean operating time for recanalization 
and EVG insertion was 2.5 hours, and the mean 
blood loss was 182 ml (Table II). Four patients were 
classified as type I, two as type II, and one as type III 
(Table II; Fig. 9). The EVGs were anastomosed 
distally to the common femoral artery (3), the deep 
femoral artery (3), and the superficial femoral artery 
(1). The EVG lengths ranged from 21 cm to 32 cm 
(mean, 26 cm; Table II). Mid-graft stenosis (2) from 
either inadequate graft expansion (1) or extraluminal 
compression (1) of the prosthesis was corrected by 
balloon dilatation (1) of  the narrowed graft segment, 
with the insertion of an additional balloon expandable 
stent (1) within the endovascular p osthetic graft. 
The anastomotic site of  the recipient artery for the 
FFB grafts was the common femoral artery in five 
patients and the deep femoral artery in two patients. 
Combined-segment occlusive disease was simulta- 
neously treated in five of the patients with a total of  
eight supplemental procedures (two femoropopliteal 
bypass procedures; six profundaplasty procedures). 
Four of  the patients underwent a partial foot ampu- 
tation at the conclusion of the arterial reconstructive 
procedures (one bilateral transmetatarsal; three sin- 
gle/multiple toe amputations). 
After endovascular aortofemoral reconstruction 
and, in some instances, a supplementary conventional 
infrainguinal surgical bypass or profundaplasty proce- 
dure, the ankle-brachial indexes significantly im- 
proved (p < 0.05, Student's paired t test) from a 
mean of  0.24 + 0.3 to 0.64 -+ 1.3 in the ipsilateral 
limb with an EVG and from a mean of 0.09 + 0.2 to 
0.70 + 0.2 in the contralateral limb. As shown in Fig. 
10, the thigh PVR amplitudes also improved from a 
mean of 9.0 + 3 mm to a mean of 29.9 -+ 7 mm in 
the limb ipsilateral to the EVG and from a mean of  
6.1 _+ 2 mm to a mean of  26A -+ 4 mm in the 
contralateral limb (p < 0.05, Student's paired t test): 
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Fig. 3. Surgical procedure for endovascular g afting The 
side for graft insertion is selected by using algorithm shown 
in Fig. 2. Because this case is type I, stenosed side is chosen 
for recanalization. 7F introducer sheath is inserted via an 
open arteriotomy in femoral artery. Care must be taken to 
puncture artery at the center of the planned anastomosis 
site for subsequent FFB. Recanalization wire and direc- 
tional catheter are inserted through the sheath. An effort is 
made to direct recanalization wire and catheter within the 
stenosed lumen or within the intraintimal layer of occluded 
artery. 
There were no early or late graft failures during the 
follow-up period, which ranged from 9 to 28 months 
(mean, 17 months).  One patient died of  myocardial 
infarction 19 months after surgery. Limb salvage and 
wound healing were achieved in all cases. Complete 
relief o f  ischemic symptoms, including rest pain, was 
achieved in all patients. After surgery, the changes in 
clinical status were all +3  (markedly improved) ac- 
cording to the Rutherford criteria 2s (Table II). 
There were no major complications, and minor 
complications were limited to one groin hematoma 
that resolved without intervention. Two external iliac 
arteries that were severely calcified perforated uring 
.r 
I % , .  
z 
Fig. 4. After successful recanalization, 8-mm balloon an- 
gioplasty catheter is inserted over wire through a 7F intro- 
ducer sheath. Iliac artery and, in some instances, distal aorta 
are dilatated to the level of arterial entrance slte of intro- 
ducer sheath. 
balloon dilatation procedures. These perforations 
were manifested by a minimal amount o f  extralumi- 
nal contrast extravasation. However,  because these 
perforations were very small and because hemostasis 
was immediately achieved by the inflation of  an an- 
gioplasty balloon, the amount o f  blood loss was in- 
significant. After hemostasis was achieved, these dis- 
rupted vessels were safely exduded from the 
circulation by the insertion of  the EVG. 
DISCUSSION 
On the basis o f  proven durability and low mortal- 
ity rates, ABFB is an effective procedure for the treat- 
ment of  bilateral l imb-threatening ischemia s a result 
o f  aortoiliac occlusive disease. 26~3° These good re- 
sults, however, must be evaluated in the context o f  
careful patient selection that includes a substantial 
percentage of  patients with claudication (60% to 
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Fig. 5. 7F introducer sheath is removed while recanaliza- 
non wire is held in a stable positron. Using scissors, arteri- 
otomy is extended to a size that will accommodate a I4F 
delivery sheath. Under fluoroscopic control, delivery 
sheath is inserted over wire and a radiopaque Palmaz stent 
is positioned at preselected site. In this example of type I 
disease, proximal stent is deployed within distal aorta. It is 
crucial to place the stent above the proximal end of the 
atherosclerotic plaque. 
76%) as the operative indication. 26,28,29 These pa- 
tients tend to be relatively ounger and healthier than 
those patients who have advanced ischemic disease, 
and they may he expected to have a better outcome 
from treatment. These good results may not extend 
to all patient groups. For example, in a recent series 
Mason et al.2 reported a morbidity rate of 30% and a 
mortality rate of  7% in a group of  relatively high-risk 
patients who underwent ABFB. Accordingly, patients 
who have critical leg ischemia that requires a multi- 
level arterial reconstruction for advanced, bilateral 
aortoiliac atherosclerotic disease who also have severe 
medical illnesses or have had previous abdominal 
vascular surgery are likely to be at an even higher risk 
for perioperative complications from an ABFB. 
Fig. 6. After accurate posinonmg of device, tip balloon is 
deflated and outer sheath is partially retracted so that ennre 
stent is exposed. With inflation of the second balloon, the 
EVG becomes firmly fixed to the underlying arterial wall. 
Balloon catheter is then used to gently dilate the PTFE 
graft in a serial descending segmental fashion as the balloon 
is withdrawn. 
Ax-bFB has been the procedure of choice for 
treating patients who have bilateral aortoiliac occlusive 
disease and who are high surgical risks. 1,2,4-12,31-35 
Although this procedure is less physiologically stress- 
ful than ABFB and has been associated with a lower 
mortality rate than ABFB in the high-risk population, 
it is generally considered to be a compromise proce- 
dure with relatively poor patency rates.l,2,4,7-9,11,12,31 
Those investigators who do not recommend the use 
of  Ax-bFB have reported primary patency rates of 
54% to 63% and 47% to 68% at 1 and 5 years, 
respectively. 4,7-9,11,12 On the basis of these results, it 
has been suggested that the indications for Ax-bFB 
should be restricted to patients who have a major 
contraindication to the use of ABFB. Alternatively, 
Parsonnet et al. 35 and Johnson and his coworkers 1 
have recommended that axillofemoral bypass proce- 
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Fig. 7. Distal end of the EVG is endoluminally hand- 
anastomosed in a customized fashion to patent runoff ves- 
sel. Proximal anastomosis of FFB is then performed over 
the arteriotomy site. 
dures should be considered as an alternative proce- 
dure to ABFB, even ha patients who are not high 
surgical risks. This concept has been supported by 
E1-Massry et al.s3 and Taylor et al., 32 who demon- 
strated impressive primary patency rates of 78% and 
74% at 5 years, respectively, using an externally sup- 
ported PTFE graft. Solely on the basis of these excel- 
lent patency rates, Taylor et al. s2 concluded that 
Ax-bFB is an appropriate technique that deserves 
more widespread use. 
Although patency rates are clearly an important 
factor in evaluating the effectiveness ofAx-bFB, sev- 
eral additional concerns limit the value of this proce- 
dure compared with the techniques described in the 
present study. The first is the need for general anes- 
thesia. Although still controversial, recent data ob- 
............. \,, / 
Fig. 8. Completion of endovascular aortoiliac bypass and 
standard FFB. 
tained from well-designed and carefully conducted 
randomized, prospective studies have demonstrated 
substantially reduced morbidity and mortality rates 
when epidnral anesthesia was used instead of general 
anesthesia, a6-39 Yeager et al. s7 randomized 53 high- 
risk surgical patients to either general anesthesia or 
epidural anesthesia and identified asevenfold increase 
in the incidence of major infection i the general 
anesthesia group. This study also proved a significant 
benefit o the use of epidural anesthesia in terms 
of the incidence of overall morbidity, respiratory 
failure, and hospital cost. The significant benefits 
of epidural anesthesia over general anesthesia have 
been confirmed by another randomized, prospective 
study, s8'39 Endovascular grafting 0fthe lilac arteries 
may be performed under local or epidnral anesthesia, 
which may be a major advantage over conventional 
treatu~ent options in medically ill patients. 
Another factor that limits the effectiveness ofAx- 
bFB in comparison with the techniques described in 
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this study is the insufficient hemodynamic improve- 
ment that is seen in the affected limb after Ax- 
bFB. 8-12 O'Donnell et al. 11 investigated the hemody- 
namic improvement after Ax-bFB and found that 
when it was applied for limb salvage, the resolution of 
symptoms (i.e., healing of foot lesions or relief of rest 
pain) was achieved in only 24% of the cases. These 
investigators also measured the plethysmographic 
amplitude of the limb before and after surgery and 
showed that the Ax-bFB had no significant effect on 
this measurement. These findings are also consistent 
with a number of other reports that have focused on 
the same issues. 8-1°,12 The mechanism for this phe- 
nomenon is thought o be related to the relatively 
small donor artery and the high flow resistance caused 
by the lengthy bypass graft. In comparison, the he- 
modynamic and functional outcome after endovascn- 
lar grafting in the present study was very encourag- 
ing. In all cases the symptoms were completely 
relieved, along with a 3.3-fold increase in the PVR 
amplitude in the thigh. These results may be in part a 
result of the short in-line reconstruction used for 
endovascular iliac bypass. 
The final limiting factor for axillobifemoral recon- 
struction is the known wide variety of graft-related 
complications that occur after Ax-bFB, including 
graft infection, upper-arm ischemia as a result of 
thromboembolism, or disruption of the proximal 
anastomosis and perigraft seroma. Graft infection is a 
serious complication that may be accompanied by 
high moctality and amputation rates, s'7 Although 
these complications may be expected to occur at a 
certain rate whenever a prosthetic material is used, 
the reported rates after Ax-bFB (3% to 12%) are 
clearly higher than for all other prosthetic vascular 
bypass procedures. 4-s Upper-arm ischemia caused by 
thromboembolism originating from the proximal 
anastomosis another disastrous event that is re- 
ported to occur in 15% of cases. L3-6 Amputation of 
otherwise asymptomatic arms has also been reported 
as a result of thromboembolism after Ax-bFB. ~ Be- 
cause these events usually occur with occluded grafts, 
some investigators ecommend the routine detach- 
ment of the graft from the native artery? Reoperative 
axillary surgery has yet another set of associated com- 
pfications. Because of these complications, the reop- 
eration rate after Ax-bFB has been extremely high 
(35% to 44%). 4,6 
Previously we reported an initial experience with 
EVGs for the treatment of bilateral aortoiliac occlu- 
sive disease in which we described the insertion of a 
separate EVG on each side.17-2°,22 Although the con- 
cept of bilateral iliac endovascular grafting appears 
Table II. Operative characteristics and 
Follow-up 
Procedure 
Patient Aortofemoral Distal Simultaneous 
no. reconstruction reconstruction amputation 
1 Pre ABF-DFA Left fempop Bilateral TMA 
(EVG) (vein graft) 
DFA-DFA 
2 CIA-CFA - -  Left toe 
(EVG) 
CFA-CFA 
3 Aorto-SFA Bilateral 
(EVG) profundaplasty 
CFA-CFA 
4 Aorto-DFA Right Left 1 & 2 
(EVG) profundaplasty toes 
DFA-CFA 
5 Aorto-DFA Left fempop; - -  
(EVG) right 
DFA-DFA profundaplasty 
6 Aorto-CFA - -  - -  
(EVG) 
CFA-CFA 
7 Pre ABF-CFA Bilateral Right 1 & 2 
(EVG) profundaplasty toes 
CFA-CFA 
*In accordance with the classifications li ted in Fig. 2. 
l'Time required for recanalization a d EVG insertion. 
:~In accordance with the SVS/ISCVS reporting standards. 24 
§Died of MI. 
EVG, endovascular graft; Pre ABF, previous aortobifemoral graft; 
DFA, deep femoral artery; CIA, common iliac artery; CFA, com- 
mon femoral artery; SFA, superficial femoral artery; TMA, trans- 
metatarsal mputation. 
simple, the practical requirements in performing bi- 
lateral iliac recanalization may be technically de- 
manding, and a compromised result or even graft 
failure may be encountered. In contrast, because of 
the simplicity of the unilateral EVG procedure, a
satisfactory proximal anastomosis can be achieved in 
most cases. In addition to the satisfactory esults, this 
single iliac EVG technique significantly shortened the 
required intravascular maneuvering and likely re- 
duced the possibility ofintraoperative complications. 
This is reflected in the short operative time (niean, 
2.5 hr) and the minimal amount of blood loss (mean, 
182 ml). Furthermore, because the placement of an 
FFB graft is lmown to double the blood flow of the 
donor iliac artery, one can expect hat thc blood flow 
through thc single EVG will be twice the flow 
through bilateral EVGs? s,4° Given that high blood 
flow through a prosthetic graft may reduce the inci- 
dencc of thrombosis and anastomotic intimal hyper- 
plasia, we believe that this may provide an additional 
advantage. 
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Operative characteristics Follow-up 
Endovascular g aft 
Location of Length OR 
Type of Insertion Insertion proximal of EVG Type of time'/ Blood loss Out- Follow-up 
disease* side site stents (cm) anesthesia (hours) (cc) Complications come~ (months) Patency 
II Right DFA Inside 32 Epidural 3 300 - -  3+ 28 + 
previous 
ABF 
II Left CFA Proximal 24 Local 1.5 75 - -  3+ 19§ + 
CIA 
I Left SPA Aorta 30 General 3 200 - -  3+ 24 + 
I Right CFA Aorta 21 Epidural 2 300 - -  3 + 15 + 
I Right CFA Aorta 22 Epidural 2 100 - -  3+ 12 + 
III Right CFA Aorta 26 Epidural 3 100 - -  3+ 9 + 
I Left CFA Inside 28 Epidural 3 200 Wound 3 + 9 + 
previous hematoma 
ABF 
With regard to the durability of the dilated PTFE 
graft, it has been shown that the PTFE graft can be 
used safely if the dilation ratio is less than 3:1.* Given 
that all of  the inserted EVGs were surrounded and 
supported by native vessels and that the PTFE grafts 
were dilated only up to 1.2:1, we believe that the risk 
of  further graft expansion, rupture, or both after 
insertion is negligible. 
Technical success was achieved in 100% of the 
recanalization procedures attempted in this study 
without any procedural complications such as distal 
embolization. This is exceptional compared with the 
reported success rates and complication rates associ- 
ated with balloon angioplasty with or without the 
insertion of vascular stents for the treatment of iliac 
occlusions. The technical success rates ofangioplasty 
with or without stenting have been reported to range 
between 33% and 81%. 13~6 Distal embolization has 
been reported to occur at rates of  5% to 20%, and the 
overall complication rate ranges between 1I% and 
50%3 a16 The advantages of EVG procedures over 
these techniques become more apparent when con- 
sidering the clinical state of  the patients treated and 
*Wisselink W, Rodino W, Panetta TF, et al. Characteristics of  
balloon dilated polytetrafluoroethylene grafts for endovascular 
surgery [abstract]. Meeting program of Tenth Annual Meeting 
of the Eastern Vascular Society. 
the severity of their occlusive disease. These anglo- 
plasty series contained a high percentage of patients 
who had claudication as the indication for treatment 
(50% to 91%). The percentage of patients who had 
ischemic tissue loss as an indication for treatment was 
only 0% to 8%, and the mean lesion length was 5.1 to 
6.4 cm. In comparison, our current study included 
only those patients who had ischemic tissue loss and a 
mean lesion length of 15.4 _+ 5.2 cm There axe 
severn factors that support he treatment of aortoiliac 
occlusive disease with EVGs rather than percutane- 
ous angioplasty and stenting. When performing per- 
cutaneous angioplasty, arterial rupture during bal- 
loon dilatation will result in an acute procedural 
failure and necessitate surgical correction. It is for this 
reason that overdilatation should be avoided. 15 
Avoiding overdilatation may prevent rupture, but it 
may also be partly responsible for the disappointing 
patency rates after percutaneous therapy because 
overdilatation of the lesion to overcome lastic recoil 
may be a crucial part of the procedure. In the current 
series, two arterial ruptures were detected during 
dilatation. These lesions, however, were safely ex- 
cluded from the circulation by the insertion of an 
EVG. Accordingly, arterial perforation during vessel 
dilatation for EVG insertion did not result in a pro- 
cedure complication and is likely to occur while cre- 
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Fig. 9. A, Preoperative arteriogram of patient no. 5 demonstrates that the right iliac artery 
system is diffusely stenosed and occluded from its origin on the left side. Because the right 
internal iliac artery is negligible (type I), the right side was chosen for recanalization a d graft 
insertion. Pelvic circulation is maintained by the inferior mesenteric artery (open arrow). B, 
Completion arteriogram of patient no. 5. By placing the stent (S) above the lesion (within distal 
aorta), a good angiographic result was obtained. C, Arch arteriogram of patient no. 5 reveals a
90% stenosis at the origin of the innominate artery and occluded left common carotid and 
subclavian arteries. Unrecognized inflow disease may have contributed to failure of two previous 
axillofemoral bypass procedures. 
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Fig. 10. Hemodynamic improvement after endovascular g afting. After EVG bypass proce- 
dure, thigh PVR amplitudes increased from 9 - 3 mm to 30 + 7 mm on the side ipsilateral to 
EVG insertion and from 6 + 2 mm to 24 + 4 mm on the contralateral side. 
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ating a wide tract into which the EVG will be in- 
serted. All procedures in the current study were 
performed through open access ites. This approach 
may reduce the chance for distal embol izat ion be- 
cause control of  the inflow to the distal arteries can be 
uniformly obtained. Addit ional advantages to an 
"open"  cut -down technique include the ability to 
perform this procedure even in the presence of a 
common femoral artery occlusion or when a standard 
infrainguinal bypass or associated procedure is re- 
quired (i.e., endarterectomy, profimdaplasty). 
We have successfully performed bilateral aor- 
toiliac reconstructions by using an EVG combined 
with a standard FFB. A l though the number  of cases in 
which these combined techniques were used is lim- 
ited, this technique appears to be a safe and effective 
alternative for treating bilateral multilevel occlusive 
disease, especially in patients who have contraindica- 
tions to ABFB. A l though an analysis of a larger group 
of  patients over a longer period of  t ime will be re- 
quired to determine the long-term success, the short 
life expectancy of  the high-risk populat ion in this 
study may justify this approach to l imb-threatening 
aortoiliac occlusive disease. 
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DISCUSSION 
Dr. R. Clement Darl ing I I I  (Albany, N.Y.). I would 
like to congratulate Dr. Ohld for his ~xcellent presentation, 
and I commend the group from Montefiore for their pio- 
neering work in the field of stent gFafting. In  this study, 
seven patients who had severe, multilevel peripheral vascu- 
lar disease and critical ischemia were treated with the place- 
ment of unilateral stent grafts and crossover FFBs. These 
patients had significant comorbid iseases that placed them 
at substantial risk for undergoing eneral anesthesia com- 
bined with more extensive vascular surgery. The mortality 
rate in these seven patients was 0%. Technical success was 
achieved in 100%. Minimal blood loss was incurred. Overall 
the patients had a significant hemodynamic improvement. 
Two patients had perforation of external iliac arteries, 
which were treated with exclusion by the insertion of the 
endovascular device. These are truly laudable results in a 
very difficult patient population. I have a few questions for 
Dr. Ohki. 
First, what were the exclusion criteria used for the 
selection of these patients? Were there any patients who 
were excluded because of anatomic or physiologic reasons 
such as small iliac arteries, aortic occlusion, or aortoiliac 
aneurysmal disease? 
Second, how much dye was used in this procedure? Is
this procedure contraindicated in patients who have 
chronic renal insufficiency, and how do you handle patients 
who may not be able to tolerate a substantial dye load? 
Third, have you had any fixation problems with the 
proximal stent or with stent graft migration? In patients 
who have smaller distal arteries, have you had any problems 
with the distal anastomosis? 
Also, in patients with extravasation of dye from the 
external i iac artery, is it usually handled with a stent graft? 
However, would this be possible with perforation occur- 
ring in the common iliac artery? I f  you used the stent graft 
to repair these, how would you deal with the hypogastric, 
especially with regard to retrograde flow that may leak out 
the perforation? 
Finally, because your group has had such superb results 
with these severely ill patients, would you consider expand- 
ing the indications for this procedure to other patients? 
In conclusion, I commend Dr. Veith's group on his 
tremendous results with these stent grafts, I think that this 
is a revolutionary procedure, and i look forward with great 
interest o the long-term and mid-term results as to the 
patency of these grafts. 
Dr. Takao Ohki. No patients were excluded from the 
study for anatomic or physiologic reasons. The only pa- 
tients who were excluded were those who were healthy 
enough to tolerate an ABFB. We had one patient who had 
a small iliac artery, but this was not an obstacle to perform- 
ing the procedure. Although we did not encounter a case 
with a high aortic occlusion, it could be a contraindication, 
as Dr. Darling has pointed out, because the aorta might be 
filled with thrombus and maneuvering a gnidewire or a 
catheter within a thrombus has the potential of distal and, 
more importantly, proximal embolization. In the current 
series there were no cases with coexisting aortic aneurysms, 
but if we did encounter such a case, we could perform the 
so-called "Parodi procedure" to treat both the aneurysm 
and the occlusion. However, because the profile of the 
delivery system for an aneurysm is slightly larger than that 
used for occlusive disease, insertion of the device through a 
previously occluded lliac artery might be difficult. 
Although the amount of contrast medium used in this 
study was small and postoperative r nal failure did not 
develop in any of our patients, even a small amount of 
contrast dye may be harmful in the presence of severe renal 
failure. In such instances the surgeon must carefully weigh 
the benefits and the disadvantages of using an alternative 
procedure. Although an axiilofemoral bypass can be per- 
formed without using a contrast medium, the numerous 
disadvantages associated with this procedure must b e taken. 
into consideration. 
We have not had a problem with stent migration or  
fixation when treating patients who have occlusive disease. 
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We are more concerned with these complications when 
performing endovascular g afting for aneurysmal disease. 
Unlike some series that have been reported by interven- 
tional radiologists, our series dealt only with cases of isch- 
emic gangrene. Hence, we had only three patients who had 
a common femoral artery that was suitable for anastomosis 
with the EVG; in the other four cases it was either occluded 
or severely diseased. Because each procedure was per- 
formed under direct exposure of the femoral vessels, depend- 
mg on the amount of distal disease present, he distal anasto- 
mosis was easily fashioned. This fearure is a major advan- 
tage when compared with the percutaneous approach. 
If a hypogastric artery was feeding an arterial rupture 
site, we would deploy a second stent within the EVG at the 
origin of the hypogastric artery to tightly seal the graft to 
the arterial wall, thus occluding hypogastric retrograde 
flow. If this failed, the next optionwould be to obtain direct 
exposure through a retroperitoneal incision and ligate the 
feeding vessel. We believe that the ability of an EVG to 
safely treat these disrupted vessels is an advantage over 
conventional stenfing. We are, therefore, comfortable during 
balloon dilatation and do not consider iliac artery perfora- 
tion as a complication, but rather a part of the procedure. 
In regard to expanding the indications, we believe that 
this procedure isstill experimental and that many questions 
need to be answered--the most important being long-term 
parency. Accordingly, until these questions are resolved, we 
do not plan on expanding the indications to include healthy 
patients with longer life expectancies who can tolerate the 
gold standard procedure, that is, an ABFB. 
Dr. Jerry R. Youkey (Danville, Pa. j. It is my under- 
standing that the application i  this manner of these two 
combined items is perceived, at least previously, by the 
Food and Drug Administration (FDA ~, as an off-label use of 
the items, Were these studies done with Institutional Re- 
view Board approval on a compassionate-use basis? What 
would be your recommendations and perhaps your coau- 
thors to those of us who would entertain doing these kinds 
of procedures in our instatutions in regard to not inviting 
the attention of the FDA, or perhaps even more impor- 
tantly of avoiding what might be perceived as an almost 
indefensible suit? What are the liability issues if we have an 
untoward event? 
Dr. Frank I. Veith. That is indeed atough question. I 
think one of the reasons I queried Dorothy Abel so in- 
tensely was that the policy of the government up until now 
has been to accept off-label use and at least allow hospitals 
to charge for them. You will note that some previous papers 
clearly involved off-label use, including the use of the 
Wallstent in the axillary artery, so perhaps the question 
should be directed to others here rather than me. I thinl< 
our intention in the future is to get investigational device 
exemption-approval for all our off-label-use devices, and 
Dr. Marin and I are in the process of doing that. We are 
functioning ina capacity that is consistent with our institu- 
tional review board and up until now has been consistent 
with FDA and Health Care Financing Administration 
guidelines. But I think after what you heard, those guide- 
lines are changing. 
With regard to the legal liability, ou can bet your tife 
that we, and any of you who try these procedures and have 
a bad outcome, are going to be very endangered by the 
potential of a lawsuit. It would be easy for a plaintiff's 
attorney to say: Are you using your device in an FDA- 
approved manner? The answer is no. You can predict what 
your own liability is going to be. I, therefore, would urge 
anybody who gets into this field to be aware of the rislcs 
involved, because they are real We have taken them and 
have not been burned yet, but the potential dearly exists. 
This is one of the stumbling blocks to moving ahead in this 
field. 
Dr, Fredric Jarrett (Pittsburgh, Pa.). Do you or does 
anyone lse in the audience know of any liability suits that 
have occurred with endovascular g afting, which obviously 
is still in its infancy? 
Dr. Ohld. I do not know, but I am sure they do exist. 
We have been threatened by such suits, and fortunately 
they have not occurred. But the possibility is a major risk 
involved with using materials in an off-label fashion. How- 
ever, it is done every day by every radiologist in the country 
who performs these procedures. The only stent that is 
approved for use is the P308, and other stents are being 
used routinely. So this is not just a problem that one faces in 
endovascular g afting. I am sure if you're using stents in 
your restitution, you are right in the same boat with every- 
body else who is using them off-label. So it is a real problem 
and one that has not yet been solved. [ therefore urge you 
to be careful. It is one of the reasons that we have not 
chosen to expand our indications and will not perform the 
procedures ina patient even if they have severe claudication 
and many other indications. We are afraid of the legal 
liability. 
Dr. David Caleagno (Camp Hill, Pa.). I just have a 
technical quesnon, and I think I know how you would 
approach it because you described how you would ap- 
proach a perforated iliac artery. It is pretty easy to get in a 
dissection plane when you're going up retrograde, and with 
your bilateral disease you can't do what they did and come 
up and over and work down. If you get in a dissection, are 
you comfortable with that as long as you pop back into the 
lumen, because you're using a graft as opposed to some of 
us that just do balloon dilation, or do yon abort the 
procedure? 
Dr. Ohki. Ifa guidewire traverses the subintimal p ane 
during recanalization, then using a directional catheter we 
try to reenter the true lumen before entering the aorta. 
Although this may not always be possible, it is more of a 
problem when one has to maintain contralateral iliac flow. 
Because we usually do not have to be concerned about 
contralateral flow. we can even place the proximal stent in 
the aorta and fix the dissection at the same time. Prograde 
recanalization through the axillary artery is another option. 
We have never had to abort a procedure because of this 
problem. 
